54 Folgen

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.

The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.

MAP - Market Access Podcast Dr. Stefan Walzer

    • Wirtschaft
    • 5,0 • 3 Bewertungen

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.

The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.

    Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.

    Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.

    🎧 Excited to share our CEO, Dr. Stefan Walzer's newest Market Access podcast episode that's nothing short of a masterclass for healthcare startups venturing into the European market!
    In this engaging episode, Dr. Walzer sits down with Dr. Thomas Kerscher and Mark Anken, both titans in the healthcare and pharmaceutical sectors with over two decades of experience. Currently at the helm of advantage, they're shaping the future of startups in this complex field. 🌍
    Key Highlights:
    1️⃣ Tailored Strategies: The critical need for startups to tailor their strategies based on product type and the unique healthcare landscapes of European countries.
    2️⃣ Realistic Approach: The importance of balancing optimism with realism, especially when pitching to well-informed investors.
    3️⃣ Scaling Up: The power of starting small, akin to Airbnb's model, then scaling up based on market feedback and minimal business model alterations.
    4️⃣ Innovation vs. Reimbursement: Understanding the delicate balance between being innovative and navigating the reimbursement strategies crucial for startup viability.

    💡 The duo shares invaluable insights on the significance of understanding your target customer, the nuances of entering varied European markets, and the complexities startups face in aligning their business models with healthcare policies. They stress the importance of innovation, not just for product differentiation, but as a tool to address cost pressures in healthcare systems.

    📈 For those in healthcare startups, this episode is a goldmine of advice on developing effective business plans, understanding investor expectations, and the imperative of global market awareness.

    Join us in exploring these vital topics, and gain a wealth of knowledge to propel your healthcare startup to new heights. Don't miss out on this incredible episode for a roadmap to success in the challenging yet rewarding realm of healthcare entrepreneurship.

    #HealthcareStartups #MarketAccess #Podcast #Innovation #BusinessStrategy #HealthcareInvestment #EuropeanMarket #DrStefanWalzer

    👉 Tune in to the full episode for a deep dive into these groundbreaking insights! 🎙️👇

    • 34 Min.
    How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?

    How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?

    🎙️ Exciting Podcast Episode Is Here! 🎙️
    In this episode of our podcast series, I'm excited to share that Stefan Walzer, a seasoned reimbursement expert, hosts the incredibly talented Amelie Moser, a business consultant with two decades of unparalleled expertise in market access!
    🎯 What's Happening?
    Immerse yourself in the fascinating world of digital health and see how it sharply contrasts with traditional drug landscapes.
    Grasp the challenges of moving global product strategies into local implementations, all through the lens of Aurelies experience.
    Navigate the crucial role of ecosystem mapping, and learn why it's important to engage all stakeholders.
    💡 Key Takeaways:
    Experience the dynamic nature of strategy adaptation — it's an evolving process, not just a set document!
    Join in on an enlightening discussion about the mindset shift crucial for companies making the leap from global to local viewpoints.
    Gain perspective on balancing qualitative vs. quantitative data for local market achievement.
    Uncover the unexplored complexities of digital health solutions and the challenges they pose.
    ✨ Special Mention: Dive deep with Aurelie as she discusses her founding venture, BAMBOOSTER, and how she plays a crucial role in connecting top pharma giants with startups in the digital health and AI sectors.
    If the evolving landscape of healthcare piques your curiosity as much as it does mine, you won't want to miss this episode. Listen now for this enlightening conversation! 🚀
    🔗 Find the 3C Business Model Canvas here.

    ✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

    MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
    #DigitalHealth #MarketAccess #Podcast #HealthcareInnovation #LocalVsGlobal #StrategiesForSuccess

    • 32 Min.
    AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?

    AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?

    Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!
    🚀 Dive Deep into the Core of Pharmaceutical Reforms!
    Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀

    🌎 Explore the Global Impact!
    Navigate through their insightful discussion on how these reforms potentially sculpt Germany’s presence on the global stage, especially in the orphan drugs market, and assess Germany's unique positioning in evaluating them! 🌎

    💡 Illuminating the Opaqueness of Drug Pricing!
    Embark on a journey through the complexities and pragmatic implications of drug pricing, dissecting the nuances of arbitration boards, pricing mechanisms, and the often intricate physician prescription behaviors amidst the recent reforms. 💡

    🤔 Facing the Challenges Head-On!
    Explore the potential disconnect between pricing strategies and actual prescription practices, as our experts shed light on the vital need for enhancing transparency and communication with physicians regarding pricing negotiations and adjustments. 🤔

    👥 Join Matthias and Stefan as they scrutinize the germane issues of drug pricing, contemplate future adjustments within the system, and ponder upon the possible shifts influenced by the upcoming national elections and continual changes within the healthcare landscape! 👥

    🎧 Tune in to immerse yourself in a conversation that not only explores the multidimensional aspects of the healthcare and pharmaceutical reimbursement system but also poses potent questions regarding its future amidst regulatory and structural shifts! 🎧

    A journey through the dynamics of pharmaceutical pricing and reforms awaits you, amplifying both economic and patient care perspectives amidst the shifting tides of the healthcare system in Germany! Don’t miss it! 🚀🚀

    • 31 Min.
    Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?

    Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?

    Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
     
    Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“. 
    Dr. Heiner Sandmeier has been part of the drug evaluation committee advising the Swiss decision makers for over a century and opens his insights and secrets to all listeners. 
    Some of the topics Dr. Sandmeier and reimbursement veteran Dr. Stefan Walzer discuss are as follows: 
    What are the main drivers for a positive decision in Switzerland?Who is involved in the decision process?What are the challenges as well as possible solutions for the main issues?What are the differences to other countries in Europe?
    And last but not least: Why should you still consider to enter the Swiss market with an innovative pharmaceutical product?
    ✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

    MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

    #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #pricingstrategy #negotiations #pricing #pharmaceuticals #switzerland #innovation #reimbursement

    • 36 Min.
    How should market access and medical affairs work together, Dr. Mike Rosenblatt?

    How should market access and medical affairs work together, Dr. Mike Rosenblatt?

    Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi
    We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:
    - What are the differences between Clinical Development and Medical Affairs?
    - When should a company start telling their medical story about a new product?
    - What are the differences between drugs and vaccinations from a medical affairs’ perspective?
    - And how should market access and medical affairs ideally work together?
    Market access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access continued their come together in Boston in May 2023 in this epic podcast episode. 
    Don’t miss this amazing conversation. 
     
    ✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
    MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf
    #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #medicalaffairs #pricingstrategy #negotiations
    #pricing #medtech #pharmaceuticals #usa #innovation #vaccination 

    • 30 Min.
    📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?

    📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?

    🎧 Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi  
    🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems... 
    💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisation! In this MAP podcast episode, health care system veteran Dr. Stefan Walzer and Dr. Peter Indra are discussing the current state of digital health in Switzerland, possible improvements and the inspiring example of Estonia.
    What are we talking about, when we address the topic of digitalisation and e-health?
    Data + AI, which is dealing with the dataInfrastructure like electronic patient record and vaccination registriesProcesses 
    Don't miss this inspiring conversation with spill-overs for all countries around the world. 
    ✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb
    MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

    #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #digitization #digitalhealth #funding #ehealth #healthcare #digitalisation #healthservices #switzerland

    • 29 Min.

Kundenrezensionen

5,0 von 5
3 Bewertungen

3 Bewertungen

Top‑Podcasts in Wirtschaft

Teresa Stiens, Christian Rickens und die Handelsblatt Redaktion, Handelsblatt
WELT
Philipp Westermeyer - OMR
Finanzfluss
Noah Leidinger, OMR
Lena Jesberg, Anis Mičijević, Sandra Groeneveld, Kevin Knitterscheidt

Das gefällt dir vielleicht auch